Merkel Cell Carcinoma Treatment Global Market Report 2024

The global merkel cell carcinoma treatment market has grown strongly in recent years. It will grow from $3.38 billion in 2023 to $3.56 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to rising incidence of merkel cell carcinoma cases, patient and physician awareness, rising treatment options, rise of combination therapy.

The global merkel cell carcinoma treatment market is expected to see steady growth in the next few years. It will grow to $4.24 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to rise of targeted therapys, improved diagnostic techniques, growing use of precision medicine, the rise of personalized medicine. Major trends in the forecast period include advancements in early detection, development of new drug delivery systems, increasing use of biomarkers to diagnose, immunotherapy advancements, growing digital health technologie.

The anticipated rise in the incidence rate of skin cancer cases is expected to drive the expansion of the merkel cell carcinoma treatment market in the future. Skin cancer represents a specific type of cancer originating in the skin cells, occurring when normal skin cells undergo genetic mutations, leading to uncontrolled growth and the development of malignant tumors. Merkel cell carcinoma (MCC) is closely associated with skin cancer, as it is a rare and aggressive form that typically emerges from Merkel cells, specialized skin cells responsible for touch sensation. For example, in January 2023, the American Cancer Society Inc., a US-based voluntary health organization, reported approximately 97,610 new melanoma cases, with an estimated 7,990 people expected to succumb to the disease in 2023 in the US. Additionally, in July 2022, Melanoma UK, a UK-based charity organization, noted that the World Health Organization (WHO) predicts a 9% increase in melanoma skin cancer cases by 2025, with nearly 22,886 people projected to be diagnosed with melanoma skin cancer by 2040. Consequently, the growing incidence of skin cancer cases is a driving factor behind the expansion of the merkel cell carcinoma treatment market.

The merkel cell carcinoma treatment market is expected to experience growth due to the increasing demand for chemotherapy. Chemotherapy is a systemic treatment that targets cancer cells throughout the body via the bloodstream, making it effective against cancer cells that may have metastasized to distant sites. The rising demand for chemotherapy is a significant factor in the treatment of Merkel cell carcinoma (MCC). Chemotherapy is commonly used to treat advanced cases of Merkel cell carcinoma. For example, a report from Healthcare IT News in February 2022 highlighted that the demand for cancer chemotherapy is projected to increase from 10 million to 15 million by 2040, as indicated by the UICC (Union for International Cancer Control). Therefore, the growing demand for chemotherapy is a driving force behind the expansion of the merkel cell carcinoma treatment market.

The growth of the Merkel cell carcinoma treatment market in the forecast period may be hampered by a shortage of skilled oncologists. The absence of well-trained oncologists can result in delayed diagnosis and treatment, higher chances of complications, reduced demand for Merkel cell carcinoma therapeutics, an increased risk of treatment errors, and decreased patient satisfaction. To illustrate, as reported by the American Society of Clinical Oncology (ASCO) in 2022, there is a projected shortage of 2,393 oncologists anticipated by the year 2025. As a result, the deficiency of skilled oncologists is impeding the Merkel cell carcinoma treatment market's progress.

Prominent companies operating in the Merkel cell carcinoma treatment market are actively concentrating on introducing innovative products and obtaining regulatory approvals to secure a competitive advantage in the industry. The approval of new products is a pivotal aspect of the Merkel cell carcinoma treatment sector, as it ensures the safety and efficacy of medical devices and drugs for patient use. For instance, in March 2023, Incyte Corporation, a US-based biopharmaceutical company, announced the FDA (Food and Drug Administration) approval of Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting the programmed death receptor-1 (PD-1), for the treatment of individuals with locally advanced Merkel cell carcinoma (MCC) that has either metastasized or recurred. The approval of Zynyz provides healthcare providers with additional first-line treatment options for Merkel cell carcinoma, potentially leading to sustained responses in patients with advanced disease. Zynyz is administered through a 500 mg intravenous infusion lasting 30 minutes, repeated every four weeks until disease progression, intolerable toxicity, or a maximum of 24 months of treatment have been reached. This represents a significant development in the field of Merkel cell carcinoma treatment and highlights the ongoing efforts of companies to bring innovative therapies to patients in need.

In May 2023, CohBar Inc., a biotechnology company based in the United States, completed a merger with Morphogenesis Inc., and the financial details of the merger were not disclosed. This merger positions CohBar to advance its innovative late-stage clinical immuno-oncology pipeline, which includes therapies for a range of conditions such as cutaneous melanoma, Merkel cell carcinoma, head and neck cancer, and basal cell carcinoma. The newly merged entity is expected to operate under the name 'TuHURA Biosciences, Inc.' and will focus on the development of a personalized cancer vaccine platform as well as preclinical tumor microenvironment modulators. Morphogenesis Inc., a US-based company, specializes in the development of novel personalized cancer vaccines and therapies, particularly in the context of Merkel cell carcinoma treatment. This merger represents a strategic move to combine resources and expertise to further advance research and development efforts in the field of immuno-oncology and personalized cancer treatments.

Major players in the merkel cell carcinoma treatment market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche AG, Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ono Pharmaceutical Co Ltd, Millennium Pharmaceuticals Inc., Seattle Genetics Inc., Lupin Ltd., BeiGene Ltd, Siemens AG, Canon Medical Systems Corporation, NantKwest Inc., Immune Design Corporation, Oncovir Inc., ImmunityBio Inc., OncoSec Medical Inc.

Asia-Pacific was the largest region in the merkel cell carcinoma treatment market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in merkel cell carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the merkel cell carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary methods for diagnosing and treating Merkel cell carcinoma are physical examination, sentinel node biopsy, and imaging tests. A physical examination involves a thorough assessment of the patient's body. Treatment options encompass surgical excision, micrographic surgery, radiation therapy, chemotherapy, and other approaches, which can be administered orally or through injections. These treatments are accessible through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and are utilized in hospitals, home care settings, specialty centers, and more.

This report provides merkel cell carcinoma treatment market statistics, including merkel cell carcinoma treatment industry global market size, regional shares, competitors with a merkel cell carcinoma treatment market share, detailed merkel cell carcinoma treatment market segments, market trends and opportunities and any further data you may need to thrive in the merkel cell carcinoma treatment industry. This merkel cell carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The merkel cell carcinoma treatment market consists of revenues earned by entities by providing chemotherapy, immunotherapy and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The merkel cell carcinoma treatment market also includes sales of Pembrolizumab, Avelumab and Nivolumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.